These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 38635805)
1. Induction of neutralizing antibodies against SARS-CoV-2 variants by a multivalent mRNA-lipid nanoparticle vaccine encoding SARS-CoV-2/SARS-CoV Spike protein receptor-binding domains in mice. Zhang Q; Tiwari S; Wen J; Wang S; Wang L; Li W; Zhang L; Rawling S; Cheng Y; Jokerst J; Rana TM PLoS One; 2024; 19(4):e0300524. PubMed ID: 38635805 [TBL] [Abstract][Full Text] [Related]
2. Induction of neutralizing antibodies against SARS-CoV-2 variants by a multivalent mRNA-lipid nanoparticle vaccine encoding SARS-CoV-2/SARS-CoV Spike protein receptor-binding domains. Zhang Q; Tiwari SK; Wang S; Wang L; Li W; Zhang L; Rawlings SA; Cheng Y; Jokerst JV; Rana TM bioRxiv; 2022 Apr; ():. PubMed ID: 35547843 [TBL] [Abstract][Full Text] [Related]
3. A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice. Brandys P; Montagutelli X; Merenkova I; Barut GT; Thiel V; Schork NJ; Trüeb B; Conquet L; Deng A; Antanasijevic A; Lee HK; Valière M; Sindhu A; Singh G; Herold J Front Immunol; 2022; 13():912898. PubMed ID: 35874687 [TBL] [Abstract][Full Text] [Related]
4. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination. Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P Front Immunol; 2022; 13():816389. PubMed ID: 35464418 [TBL] [Abstract][Full Text] [Related]
5. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290 [TBL] [Abstract][Full Text] [Related]
6. Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants. Honda-Okubo Y; Bowen R; Barker M; Bielefeldt-Ohmann H; Petrovsky N Vaccine; 2023 Nov; 41(48):7116-7128. PubMed ID: 37863669 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models. Corleis B; Hoffmann D; Rauch S; Fricke C; Roth N; Gergen J; Kovacikova K; Schlottau K; Halwe NJ; Ulrich L; Schön J; Wernike K; Widera M; Ciesek S; Mueller SO; Mettenleiter TC; Maione D; Petsch B; Beer M; Dorhoi A Nat Commun; 2023 Feb; 14(1):816. PubMed ID: 36781853 [TBL] [Abstract][Full Text] [Related]
9. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082 [TBL] [Abstract][Full Text] [Related]
10. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines. Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378 [TBL] [Abstract][Full Text] [Related]
11. Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit. Hsieh HC; Chen CC; Chou PH; Liu WC; Wu SC Antiviral Res; 2023 Dec; 220():105752. PubMed ID: 37949318 [TBL] [Abstract][Full Text] [Related]
12. A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern. Lee IJ; Lan YH; Wu PY; Wu YW; Chen YH; Tseng SC; Kuo TJ; Sun CP; Jan JT; Ma HH; Liao CC; Liang JJ; Ko HY; Chang CS; Liu WC; Ko YA; Chen YH; Sie ZL; Tsung SI; Lin YL; Wang IH; Tao MH Emerg Microbes Infect; 2023 Dec; 12(1):2149353. PubMed ID: 36395071 [TBL] [Abstract][Full Text] [Related]
13. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice. Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595 [TBL] [Abstract][Full Text] [Related]
14. A Cocktail of Lipid Nanoparticle-mRNA Vaccines Broaden Immune Responses against β-Coronaviruses in a Murine Model. Zhang Y; Zhang J; Li D; Mao Q; Li X; Liang Z; He Q Viruses; 2024 Mar; 16(3):. PubMed ID: 38543849 [TBL] [Abstract][Full Text] [Related]
15. Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2. Jawalagatti V; Kirthika P; Hewawaduge C; Yang MS; Park JY; Oh B; Lee JH Mol Ther; 2022 May; 30(5):1926-1940. PubMed ID: 35123065 [TBL] [Abstract][Full Text] [Related]
16. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination. Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434 [TBL] [Abstract][Full Text] [Related]
17. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity. Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524 [TBL] [Abstract][Full Text] [Related]
18. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination. Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410 [TBL] [Abstract][Full Text] [Related]
19. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM Elife; 2022 Aug; 11():. PubMed ID: 36004719 [TBL] [Abstract][Full Text] [Related]